MedTrace Logo

Pilot Study of Hypertrophic Cardiomyopathy & Implantable Cardioverter Defibrillator Assessment: (Subcutaneous vs Transvenous)

NCT05938283 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-02-19

No results posted yet for this study

Summary

Pilot randomised trial to assess recruitment for a larger trial to compare the efficacy and adverse effects of the subcutaneous and transvenous ICD in patients with hypertrophic cardiomyopathy (HCM) and indication for ICD therapy, with no requirement for pacing

Conditions

  • Implantable Defibrillator User
  • Hypertrophic Cardiomyopathy
  • Implantable Cardioverter Ventricular Lead Dysfunction or Complication
  • Ventricular Arrythmia

Interventions

DEVICE

Implantable Cardioverter Defibrillator implant

ICD implant to protect patients from life threatening ventricular tachycardia or ventricular fibrillation

Sponsors & Collaborators

  • Boston Scientific Corporation

    collaborator INDUSTRY

  • Queen Mary University of London

    collaborator OTHER

  • Barts & The London NHS Trust

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-10
Primary Completion
2026-01-07
Completion
2026-01-07

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05938283 on ClinicalTrials.gov